Paris-based Sanofi established its first digital manufacturing facility for biologics production in Framingham, Mass.
The new facility will manufacture biologics for Sanofi's specialty care segment, the French drugmaker said in an Oct. 15 news release.
The production facility is part of Sanofi's move to focus on biologics-based therapies as the company transforms its research and development pipeline.
Sanofi aims to increase levels of productivity, agility and flexibility using the manufacturing site's advanced technologies, the company added.
The company plans to expand its digital transformation initiative in its facilities in Toronto, as well as in Suzano, Brazil; Waterford, Ireland; Sisteron, France; and Geel, Belgium.